Business Description
Moderna Inc
NAICS : 325412
SIC : 2836
ISIN : US60770K1079
Compare
Compare
Traded in other countries / regions
MRNA.USAM1RN34.Brazil0A45.UK0QF.Germany1MRNA.ItalyMRNA.MexicoMRNA.AustriaMRNA.Peru0QF.BulgariaMRNA_KZ.Kazakhstan IPO Date
2018-12-07Description
Moderna is a commercial-stage biotech that was founded in 2010 and had its initial public offering in December 2018. The firm's mRNA technology was rapidly validated with its covid vaccine, which was authorized in the United States in December 2020. Moderna had 40 mRNA development candidates in clinical development as of September 2024. Programs span a wide range of therapeutic areas, including infectious disease, oncology, cardiovascular disease, and rare genetic diseases.
Financial Strength
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 5.07 | |||||
| Equity-to-Asset | 0.76 | |||||
| Debt-to-Equity | 0.11 | |||||
| Debt-to-EBITDA | -0.68 | |||||
| Piotroski F-Score | 3/9 | |||||
| Altman Z-Score | 3.8 | |||||
| Beneish M-Score | -2.41 | |||||
| WACC vs ROIC | ||||||
Growth Rank
4/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | 190.8 | |||||
| 3-Year EBITDA Growth Rate | -64.8 | |||||
| 3-Year EPS without NRI Growth Rate | -83.9 | |||||
| 3-Year Book Growth Rate | 78.1 | |||||
| Future 3-5Y EPS without NRI Growth Rate | 16.42 | |||||
| Future 3-5Y Total Revenue Growth Rate | -17.1 |
Momentum Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 47.4 | |||||
| 9-Day RSI | 44.04 | |||||
| 14-Day RSI | 42.28 | |||||
| 6-1 Month Momentum % | -64.19 | |||||
| 12-1 Month Momentum % | -56.92 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 4.39 | |||||
| Quick Ratio | 4.2 | |||||
| Cash Ratio | 3.12 | |||||
| Days Inventory | 79.22 | |||||
| Days Sales Outstanding | 66.73 | |||||
| Days Payable | 81.61 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | 1.4 | |||||
| Shareholder Yield % | -0.73 |
Profitability Rank
3/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Gross Margin % | 67.29 | |||||
| Operating Margin % | -53.26 | |||||
| Net Margin % | -43.99 | |||||
| FCF Margin % | -78.24 | |||||
| ROE % | -17.44 | |||||
| ROA % | -12.92 | |||||
| ROIC % | -28.85 | |||||
| ROC (Joel Greenblatt) % | -79.5 | |||||
| ROCE % | -16.23 | |||||
| Years of Profitability over Past 10-Year | 2 |
GF Value Rank
5/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PS Ratio | 3.1 | |||||
| PB Ratio | 1.31 | |||||
| Price-to-Tangible-Book | 1.32 | |||||
| EV-to-EBIT | -4.31 | |||||
| EV-to-Forward-EBIT | -2.66 | |||||
| EV-to-EBITDA | -5.03 | |||||
| EV-to-Forward-EBITDA | -3 | |||||
| EV-to-Revenue | 1.97 | |||||
| EV-to-Forward-Revenue | 3.13 | |||||
| EV-to-FCF | -2.54 | |||||
| Price-to-Projected-FCF | 0.45 | |||||
| Price-to-Net-Current-Asset-Value | 2.67 | |||||
| Price-to-Net-Cash | 5.16 | |||||
| Earnings Yield (Greenblatt) % | -23.2 | |||||
| FCF Yield % | -25.43 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:MRNA
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Moderna Inc Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | 5,056 | ||
| EPS (TTM) ($) | -5.82 | ||
| Beta | 1.38 | ||
| Volatility % | 68.82 | ||
| 14-Day RSI | 42.28 | ||
| 14-Day ATR ($) | 2.544181 | ||
| 20-Day SMA ($) | 41.9395 | ||
| 12-1 Month Momentum % | -56.92 | ||
| 52-Week Range ($) | 35.8 - 170.47 | ||
| Shares Outstanding (Mil) | 384.82 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 3 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Moderna Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Moderna Inc Stock Events
| Event | Date | Price($) | ||
|---|---|---|---|---|
| No Event Data | ||||
Moderna Inc Frequently Asked Questions
What is Moderna Inc(MRNA)'s stock price today?
The current price of MRNA is $40.13. The 52 week high of MRNA is $170.47 and 52 week low is $35.80.
When is next earnings date of Moderna Inc(MRNA)?
The next earnings date of Moderna Inc(MRNA) is 2025-02-21 Est..
Does Moderna Inc(MRNA) pay dividends? If so, how much?
Moderna Inc(MRNA) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers